Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EN3342 is a long-acting subcutaneous implant of risperidone developed for the treatment of schizophrenia. It utilizes the MedLaunch implant technology, which consists of a non-biodegradable, flexible polyurethane-based reservoir designed to provide continuous, near zero-order release of risperidone over a six-month period. Risperidone is an atypical antipsychotic that acts as an antagonist at dopamine D2 and serotonin 5-HT2A receptors. Originally developed by Endo Pharmaceuticals, the program was acquired by Braeburn Pharmaceuticals in 2015 and redesignated as BB0817. The implant technology aims to improve patient compliance by providing consistent medication levels and reducing the burden of daily dosing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EN3342.